- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03220009
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Descripción general del estudio
Estado
Condiciones
- Carcinoma de cuello uterino
- Melanoma recurrente
- Carcinoma vaginal
- Carcinoma de esófago
- Melanoma de las mucosas
- Melanoma mucoso de cabeza y cuello
- Melanoma de la mucosa de la cavidad oral
- Cáncer de vulva en estadio II AJCC v7
- Cáncer de vulva en estadio III AJCC v7
- Cáncer de vulva en estadio IIIA AJCC v7
- Cáncer de vulva en estadio IIIB AJCC v7
- Cáncer de vulva en estadio IIIC AJCC v7
- Stage IV Oral Cavity Cancer AJCC v6 and v7
- Stage IV Vulvar Cancer AJCC v7
- Cáncer de cavidad oral en estadio IVA AJCC v6 y v7
- Cáncer de cavidad oral en estadio IVB AJCC v6 y v7
- Cáncer de cavidad oral en estadio IVC AJCC v6 y v7
Descripción detallada
PRIMARY OBJECTIVES:
I. Recurrence free survival (RFS) in patients with mucosal melanoma (MM) treated with neoadjuvant ipilimumab plus nivolumab and surgery followed by adjuvant nivolumab and expectant observation.
SECONDARY OBJECTIVES:
I. Pathologic complete response with neoadjuvant ipilimumab plus nivolumab. II. Distant recurrence-free survival (DRFS) with adjuvant nivolumab and expectant observation.
III. Overall survival (OS) with adjuvant nivolumab and expectant observation. IV. Safety/toxicity as measured by maximum grade adverse event in (a) the neoadjuvant setting, (b) the adjuvant nivolumab cohort after randomization, and (c) the observation cohort after randomization.
V. Rate of delayed primary surgery.
TERTIARY OBJECTIVES:
I. Demonstrate that baseline tumors harboring a higher neoepitope burden have superior median RFS than those who have a lower neoepitope burden in the arm receiving adjuvant nivolumab.
II. Demonstrate that tumors with higher CD8+ infiltration at the tumor invasive margin at surgical resection have superior median RFS than those with lower CD8+ infiltration.
III. Demonstrate that tumors harboring a "T cell inflamed" ribonucleic acid (RNA) expression signature at surgical resection following neoadjuvant nivolumab plus ipilimumab have a superior distant RFS than those harboring a "non-T cell inflamed" signature, both in the overall group and within those who receive adjuvant nivolumab.
IV. Identify recurrent genetic alterations at baseline that are associated with higher CD8+/PD1+ infiltration at baseline and following 1 dose of neoadjuvant nivolumab plus ipilimumab.
V. Tumor response rate will be estimated based on patients whose imaging are captured and submitted during the neo-adjuvant portion of the study (imaging is not required).
OUTLINE:
PART I: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant radiation therapy (RT), if clinically appropriate.
PART II: Within 84 days of last surgical resection, patients are randomized to 1 of 2 arms.
ARM I: Patients undergo active surveillance for 1 year.
ARM II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 90 days for 2 years, every 180 days for 3 years or until disease progression, whichever is first, and every 6 months thereafter until a maximum of 5 years following registration.
Tipo de estudio
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Alliance for Clinical Trials in Oncology
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- STEP 1 ELIGIBILITY CRITERIA
Documentation of disease:
- Histologic documentation: histologically proven mucosal melanoma by local pathology
- Tumor tissue: tumor tissue from the primary site of disease must be available for PD-L1 testing (stratification factor)
Disease status
- Tumors must have NOT been completely resected, or must be locoregionally recurrent if previously resected; tumor must be deemed potentially resectable by local surgeon
- MM arising from the head/neck, genitourinary, or gastrointestinal tract
Disease meets any 1 of 4 characteristics:
- Regional lymph node (LN) involvement; OR
- Multifocal/satellite primary disease; OR
Single localized, primary disease meeting one of the following site-specific requirements:
- Head/neck - any primary lesion if sinonasal; pT4a or above for nasal or oral cavity
- Anorectal - any primary lesion
- Conjunctiva - any primary lesion T2 or T3 stage by American Joint Committee on Cancer (AJCC)
- Vaginal/cervical - any primary
- Vulvar (hair bearing surface, labia majora) - AJCC cutaneous stage IIB or higher
- Esophageal - any primary
- Locoregionally recurrent following prior resection
- No evidence of metastatic disease at the time of registration
- No prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy) or radiation therapy for MM, unless locoregionally recurrent; if recurrent, no prior medical or radiation therapy is allowed for the latest recurrence
No history of the following:
- Active known or suspected autoimmune disease
- Human immunodeficiency virus (HIV) with CD4+ count < 300 or detectable viral load; patients with HIV, undetectable viral load, and CD4+ count >= 300 are eligible
Known active hepatitis B or C
Hepatitis B can be defined as:
- Hepatitis B virus surface antigen (HBsAg) > 6 months
- Serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) 20,000 IU/ml (105 copies/ml), lower values 2,000-20,000 IU/ml (104-105 copies/ml) are often seen in hepatitis B virus e antigen (HBeAg)-negative chronic hepatitis B
- Persistent or intermittent elevation in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels
- Liver biopsy showing chronic hepatitis with moderate or severe necroinflammation
Hepatitis C can be defined as:
- Hepatitis C antibody (AB) positive
- Presence of hepatitis C virus (HCV) RNA
- Known active pulmonary disease with hypoxia defined as oxygen saturation < 85% on room air
Not pregnant and not nursing
- For women of childbearing potential only, a negative pregnancy test done =< 14 days prior to registration is required
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Creatinine clearance >= 30 mL/min by Modified Diet in Renal Disease (MDRD) equation or Cockcroft-Gault
Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Except in case of Gilbert disease
- AST/ALT =< 2.5 x upper limit of normal (ULN)
Thyroid-stimulating hormone (TSH) within normal limits (WNL)
- Supplementation is acceptable to achieve a TSH WNL; in patients with abnormal TSH if free T4 is normal and patient is clinically euthyroid, patient is eligible
Concomitant medications
- No systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days of registration (inhaled steroids for patients with underlying chronic pulmonary disease is acceptable as long as they meet other eligibility as listed above)
- No other planned concurrent investigational agents or other tumor directed therapy (chemotherapy, radiation) while on study
- STEP 2 ELIGIBILITY CRITERIA
Surgical resection of all gross disease
- This assessment will be made by the local investigator based on review of the operative report, pathology results, and/or radiology reports; microscopically positive margins (e.g. R1 resection) are permitted
Completion of PD-L1 testing
- Patients will be stratified as PD-L1 >= 5% versus (vs) < 5% OR inevaluable; baseline tumor will be utilized; if this returns inevaluable, efforts should be made to utilize the resected specimen
Randomization within 112 days of completion of surgical
- The primary region must be included on cross-sectional imaging (e.g. sinus/neck if arising from sinonasal primary; pelvis if genitourinary); radiographic changes considered nonspecific or possibly due to surgery or radiation are not considered evidence of disease
No significant immune-related adverse event due to the nivolumab plus ipilimumab dose received in the neoadjuvant setting, as follows:
- Any grade myocarditis, including an asymptomatic troponin elevation felt to be related to nivolumab plus ipilimumab
- Any grade neurologic complication (e.g. meningitis, encephalitis, neuropathy); study chair should be contacted if there is any question whether an adverse event (AE) was neurologic in nature
- Grade 2 or higher pneumonitis
- Grade 2 colitis
- Grade 2 or higher anemia (due to drug; unrelated anemia is not exclusionary)
- Thyroid/adrenal AEs regardless of grade that have stabilized or are clinically asymptomatic are eligible
- Fatigue, regardless of grade, is not a contraindication to randomization
- Grade 4 AST or ALT elevation
- Asymptomatic elevated amylase and lipase, regardless of grade, are not contraindications to randomization
Grade 4 rash; grade 3 rash is not a contraindication to randomization; any oropharyngeal lesions or bullous skin lesions that are suggestive of toxic epidermal necrolysis or Stevens-Johnson syndrome are contraindications to randomization regardless of the grade of rash
- If not specified above, other Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher AEs deemed possibly related to the nivolumab plus ipilimumab are exclusions to randomization; AEs that were attributable to surgery or adjuvant RT would not be contraindications to randomization
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Arm I (nivolumab, ipilimumab, surgery, active surveillance)
PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate. PART II: Patients undergo active surveillance for 1 year. |
Estudios correlativos
Dado IV
Otros nombres:
Someterse a RT
Otros nombres:
Dado IV
Otros nombres:
Someterse a cirugía
Someterse a vigilancia activa
Otros nombres:
|
Experimental: Arm II (nivolumab, ipilimumab, surgery, nivolumab)
PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate. PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity. |
Estudios correlativos
Dado IV
Otros nombres:
Someterse a RT
Otros nombres:
Dado IV
Otros nombres:
Someterse a cirugía
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Recurrence free survival (RFS)
Periodo de tiempo: From randomization to either adjuvant nivolumab or observation until evidence of disease recurrence, assessed up to 5 years
|
RFS of patients receiving adjuvant nivolumab will be compared to patients undergoing observation.
Kaplan- Meier curves will be constructed and median RFS times will be calculated for each arm.
|
From randomization to either adjuvant nivolumab or observation until evidence of disease recurrence, assessed up to 5 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Distant recurrence-free survival (DRFS)
Periodo de tiempo: From randomization to either adjuvant nivolumab or observation until a distant recurrence is observed, assessed up to 5 years
|
Will be evaluated using the Kaplan- Meier method.
Median times to DRFS will be calculated for each arm and a cox proportional hazards model will be constructed to determine if there is a DRFS benefit for patients in the adjuvant Nivolumab arm (compared to observation).
|
From randomization to either adjuvant nivolumab or observation until a distant recurrence is observed, assessed up to 5 years
|
Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Periodo de tiempo: Up to 5 years
|
Maximum grade adverse events will be summarized in each of the following settings: during the neo-adjuvant phase of the trial (i.e. from registration until a patient is randomized to adjuvant nivolumab or observation), the adjuvant nivolumab arm after randomization, he observation arm after randomization.
|
Up to 5 years
|
Overall survival (OS)
Periodo de tiempo: From randomization to either adjuvant nivolumab or observation until death due to any cause; assessed up to 5 years
|
Will be evaluated using the Kaplan- Meier method.
Median OS times will be calculated for each arm and a cox proportional hazards model will be constructed to determine if there is a DRFS benefit for patients in the adjuvant Nivolumab arm (compared to observation).
|
From randomization to either adjuvant nivolumab or observation until death due to any cause; assessed up to 5 years
|
Rate of delayed surgery
Periodo de tiempo: Up to 6 weeks after registration
|
Reasons for delay will be summarized and the rate of delay will be calculated along with a 95% confidence interval using the properties of the binomial distribution.
|
Up to 6 weeks after registration
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
CD8+ infiltration
Periodo de tiempo: Up to 5 years
|
CD8+ infiltration levels will be compared to RFS times using a cox proportional hazards model.
|
Up to 5 years
|
Neoepitope burden
Periodo de tiempo: Up to 5 years
|
Neoepitope burden will be compared to RFS using a cox proportional hazards model.
|
Up to 5 years
|
Pathologic complete response prior to surgery, for patients with imaging available
Periodo de tiempo: Up to time of surgery, assessed up to 5 years
|
The rate of pathologic complete response will be estimated using and a 95% confidence interval will be calculated using properties of the binomial distribution.
|
Up to time of surgery, assessed up to 5 years
|
Recurrent genetic alterations
Periodo de tiempo: Up to 5 years
|
Patients will be categorized by driver mutation, including BRAF, RAS family (NRAS/KRAS/HRAS), KIT, and/or NF1 alterations.
The degree of CD8+ and/or PD-L1 infiltration will be compared across various categories of driver mutation using descriptive statistics.
Pending further advances in genomic understanding of these tumors, alternate categories may be constructed.
|
Up to 5 years
|
T cell inflammation
Periodo de tiempo: Up to 5 years
|
Patients will be categorized has having a "T dell inflamed" RNA expression signature versus a "non-T cell inflamed" signature.
These groups will be compared to each other in terms of RFS times using a cox proportional hazards model.
An additional model will be constructed with randomized arm included to determine if there is an interaction between signature and arm.
|
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Alexander Shoushtari, Alliance for Clinical Trials in Oncology
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Procesos Patológicos
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias Glandulares y Epiteliales
- Neoplasias Genitales Femeninas
- Atributos de la enfermedad
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias de Cabeza y Cuello
- Enfermedades Estomatognáticas
- Enfermedades de la Boca
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Enfermedades esofágicas
- Tumores neuroendocrinos
- Nevos y Melanomas
- Enfermedades vaginales
- Enfermedades Vulvares
- Carcinoma
- Reaparición
- Melanoma
- Neoplasias Vulvares
- Neoplasias Esofágicas
- Neoplasias de la Boca
- Neoplasias vaginales
- Mecanismos moleculares de acción farmacológica
- Agentes antineoplásicos
- Agentes antineoplásicos inmunológicos
- Inhibidores de puntos de control inmunitarios
- Nivolumab
- Ipilimumab
Otros números de identificación del estudio
- NCI-2017-01239 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- U10CA180821 (Subvención/contrato del NIH de EE. UU.)
- A091603 (Otro identificador: CTEP)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Carcinoma de cuello uterino
-
Stanford UniversityTerminadoCirugía Cervical Posterior | Fusión cervical posterior | Laminectomía cervical posterior | Laminoplastia Cervical PosteriorEstados Unidos
-
Gazi UniversityReclutamientoRadiculopatía cervical | Dolor radicular cervical | Radiculitis cervical | Síndrome de la raíz cervicalPavo
-
Blaz BarunReclutamientoLesión por latigazo cervical de la columna cervicalCroacia
-
University of IcelandLandspitali University Hospital; Reykjavik University; Empowered HealthActivo, no reclutandoLesión por latigazo cervical de la columna cervicalIslandia
-
Valérie SchuermansReclutamientoEnfermedad del disco cervical | Fusión cervical | Fusión de columna | Espondilosis cervical | Hernia de disco cervical | Mielopatía cervical | Degeneración del disco cervical | Radiculopatía Cervical | Mielopatía Compresiva | Radiculopatía, Región Cervical | Radiculopatía; en espondilosis | Radiculopatía; en... y otras condicionesPaíses Bajos
-
Istanbul Medipol University HospitalTerminadoDolor | Radiculopatía cervical | Enfermedad del disco cervical | Hernia de disco cervical | Dolor radicular cervical | Cervical; HerniaPavo
-
University of MichiganWashington University School of Medicine; LFR InternationalTerminadoLesión de la vértebra cervical | Fractura de vértebra cervicalEstados Unidos
-
Ohio State UniversityMedtronicReclutamientoFusión cervicalEstados Unidos
-
University Hospital, Strasbourg, FranceTerminado
-
Ferring PharmaceuticalsTerminadoMaduración CervicalJapón
Ensayos clínicos sobre Análisis de biomarcadores de laboratorio
-
ORIOL BESTARDTerminadoTrasplante de riñón | Infección por CMVEspaña, Bélgica
-
Vanderbilt University Medical Center4DMedicalTerminado
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Aún no reclutandoInfecciones por VIH | Hepatitis B
-
Johns Hopkins UniversityReclutamiento
-
University of MiamiActivo, no reclutando
-
Hvidovre University HospitalElsassFondenTerminadoAcidosis metabólica del recién nacidoDinamarca
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... y otros colaboradoresTerminadoEnfermedades cardiovasculares | Deficiencia de vitamina D | Condiciones relacionadas con la menopausiaBrasil